GlassScriptPhysician profile
William M Mallonee
NPI 1730150467
$1,550.11
in general payments reported to CMS, 2019-2025
16 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $400 · 2020: $400 · 2021: $750.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $1,150.00 | 2020-2021 | |
| Novartis Pharmaceuticals Corporation | $135.33 | 2019 | |
| Acorda Therapeutics, INC | $48.72 | 2019 | |
| Sunovion Pharmaceuticals INC. | $40.28 | 2019 | |
| Amneal Pharmaceuticals LLC | $32.10 | 2019 | |
| Genentech USA, INC. | $30.73 | 2019 | |
| Upsher-Smith Laboratories LLC | $24.81 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $23.29 | 2019 | |
| Biogen, INC. | $15.14 | 2019 | |
| Adamas Pharmaceuticals, INC. | $14.17 | 2019 | |
| Zyla Life Sciences, INC. | $13.31 | 2019 | |
| Amgen INC. | $11.40 | 2019 | |
| Supernus Pharmaceuticals, INC. | $10.83 | 2019 |
3 companies reported research payments only; those appear in the research section below.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Mallonee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.